May 2, 2024Cancer Research

Abstract PO3-17-10: Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience

View Full Paper

Ask AI

Bookmark

Pathologic complete response was achieved in 60% of patients who underwent surgery after neoadjuvant chemotherapy.
16 of 41 patients (39%) experienced treatment interruptions due to immune related adverse events or disease progression.
Retrospective cohort study examined patients treated with pembrolizumab-based neoadjuvant chemotherapy in the UAE between October 2021 and June 2023 for early-stage triple-negative breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study shows pathologic complete response in early-stage triple-negative breast cancer, indicating support for treatment utilization.

Cite This Study

Al‐Awadhi et al. (2024) studied this question.

synapsesocial.com/papers/68e6bd41b6db64358763d894 https://doi.org/10.1158/1538-7445.sabcs23-po3-17-10

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study shows pathologic complete response in early-stage triple-negative breast cancer, indicating support for treatment utilization.

Abstract PO3-17-10: Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience

Key Points

Discussion

Implication

Cite This Study

Abstract PO3-17-10: Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider